An international biopharmaceutical company has signed a multiyear agreement with OmniComm Systems, Inc. Under the agreement, the biopharma company will initially use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple research sites to test a cancer treatment. TrialMaster EDC was selected as one of the pharmaceutical company’s preferred EDC systems based on the system’s inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important. OmniComm’s robust, compliant hosting environment was another critical factor in the selection process.